Search results

Keywords: CAR-T cells

Change search criteria ↓

12 projects found matching your search criteria:

1. Heterogeneity immunocompetent cells during chimeric antigen receptor T cell (CAR-T) CD19 immunotherapy.

Principal investigator: Aleksandra Maria Oszer

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Call: PRELUDIUM 22, Panel: NZ6
2. Overcoming CAR-T cell exhaustion via CRISPR- based enhancer modification

Principal investigator: dr Karolina Rassek

Instytut Genetyki Człowieka PAN

Call: PRELUDIUM 22, Panel: NZ6
3. Overcoming CAR-T cell exhaustion by optogenetic regulation

Principal investigator: dr Alicja Andrea Przybyszewska-Podstawka

Uniwersytet Medyczny w Lublinie

Call: PRELUDIUM 22, Panel: NZ3
4. Unveiling the molecular signature underlying resistance to CD19 CAR-T therapy in malignant cells.

Principal investigator: Marta Krawczyk

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Call: PRELUDIUM 22, Panel: NZ7
5. Unraveling protease activation in stimulated CAR-T cells to identify new biomarkers for assessing their clinical efficac…

Principal investigator: dr hab. Małgorzata Firczuk

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Call: OPUS 25, Panel: NZ7
6. Identification of circulating biomarkers for monitoring anti-CD19 CAR-T cell treatment response in patients with aggress…

Principal investigator: Monika Szelest

Uniwersytet Medyczny w Lublinie

Call: PRELUDIUM 23, Panel: NZ5
7. Identification and characterization of omics profiles in patients' serum during anti-CD19 CAR-T cell therapy

Principal investigator: Jaromir Bartosz Tomasik

Warszawski Uniwersytet Medyczny

Call: PRELUDIUM 23, Panel: NZ5
8. CAR(dio)-T(oxicity)- Engineered Heart Tissue model for CAR-T cardiotoxicity evaluation

Principal investigator: dr Agnieszka Joanna Zimna

Instytut Genetyki Człowieka PAN

Call: SONATA 19, Panel: NZ7
9. Identification of surface proteins as alternate targets for CAR-T therapy against CD19-negative tumors.

Principal investigator: dr hab. Magdalena Hanna Winiarska

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Call: PRELUDIUM BIS 2, Panel: NZ6
10. Mechanisms and consequences of CD19 loss in B-acute lymphoblastic leukaemia patients relapsing after CD19-CAR-T cell the…

Principal investigator: prof. Przemysław Juszczyński

Instytut Hematologii i Transfuzjologii

Call: PRELUDIUM BIS 3, Panel: NZ5
11. Exploring kinase hyperactivation as an innovative approach for chemo-immunotherapy for B cell acute lymphoblastic leukem…

Principal investigator: dr hab. Małgorzata Firczuk

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Call: PRELUDIUM BIS 5, Panel: NZ7
12. Depletion of the tumor microenvironment as a novel strategy potentiating the efficacy of immunotherapies.

Principal investigator: dr Małgorzata Agnieszka Bajor

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Call: OPUS 23, Panel: NZ6

Projects search

Search results